EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape

Yukesh R iD, Sushil Sharma, Madhavrao C, Gaurav Manikrao Rangari, Arup Kumar Misra, Katiboina Srinivasa Rao, Boda Srikanth Nayak, Jyothi Vennela iD, Sarikonda Sandhyarani iD

Annals of Neurosciences · 30.03.2026

DOI: 10.1177/09727531261421807 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurosciences, online erschienen am 30.03.2026. Verfasst von Yukesh R und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS) involve progressive nerve cell loss and current treatments mainly provide symptomatic relief without stopping disease progression. Drug repurposing offers a promising approach to address this gap. Metformin, a widely used oral anti-diabetic drug, is being studied in central nervous system (CNS) disorders due to its multiple effects, including activating the adenosine monophosphate–activated protein kinase (AMPK) pathway, supporting neuroprotection and promoting remyelination.

Purpose

To systematically analyse the current clinical trial landscape of metformin repurposing in CNS disorders.

Methods

Data were collected exclusively from ClinicalTrials.gov. The search focused on neurological, neurodegenerative and neurodevelopmental conditions while excluding trials mainly targeting type 2 diabetes or cancer. After screening, 23 clinical studies were selected. Extracted data emphasised disease types, therapeutic goals and measurable neurobiological and functional outcomes.

Results

Research on metformin in CNS disorders is active, with over two-thirds of trials being completed ( N = 7, 30.4%) or recruiting ( N = 9). Most studied conditions include MS ( N = 5), schizophrenia/psychosis ( N = 4) and fragile X syndrome (FXS) ( N = 4), highlighting interest in neurodevelopmental and demyelinating repair. Trials use functional outcomes such as the Timed 25-Foot Walk Test (T25FWT) and the MATRICS Consensus Cognitive Battery (MCCB), along with advanced biomarkers such as diffusion tensor imaging (DTI) for white matter integrity and molecular markers such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP).

Conclusion

This analysis shows growing interest in repurposing metformin as a potential disease-modifying therapy for CNS disorders, with a focus on neurorepair and biomarker-based assessment. Larger, well-designed randomised controlled trials are still needed to confirm efficacy in humans.

Schlagwörter

Stichwörter der Autor:innen

ClinicalTrials.govMetforminadenosine monophosphate–activated protein kinase (AMPK) pathwaydrug repurposingsystematic review

Autor:innen und Institutionen

  • Department of Pharmacology, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India.

ORCID-Profile: Yukesh R, Jyothi Vennela, Sarikonda Sandhyarani

Zitieren

APA

R, Y., Sharma, S., C, M., Rangari, G. M., Misra, A. K., Rao, K. S., Nayak, B. S., Vennela, J., & Sandhyarani, S. (2026). Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape. Annals of Neurosciences. https://doi.org/10.1177/09727531261421807

Vancouver

R Y, Sharma S, C M, Rangari GM, Misra AK, Rao KS, et al. Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape. Annals of Neurosciences. 2026. doi:10.1177/09727531261421807

BibTeX
@article{R2026,
  author = {R, Yukesh and Sharma, Sushil and C, Madhavrao and Rangari, Gaurav Manikrao and Misra, Arup Kumar and Rao, Katiboina Srinivasa and Nayak, Boda Srikanth and Vennela, Jyothi and Sandhyarani, Sarikonda},
  title = {Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape},
  journal = {Annals of Neurosciences},
  year = {2026},
  doi = {10.1177/09727531261421807}
}
Kostenlos starten →